Skip to main content

Advertisement

SpringerLink
Log in

SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment

  • Orphan Diseases (B Manger, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare autoimmune disease which, due to its clinical presentation and symptoms, is often misdiagnosed and unrecognized. Its main features are prominent inflammatory cutaneous and articular manifestations. Treatments with immunosuppressive drugs have been used for the management of SAPHO with variable results. To date, the use of anti-TNF-α agents has proved to be an effective alternative to conventional treatment for unresponsive or refractory SAPHO cases. TNF-α is a pro-inflammatory cytokine and pivotal regulator of other cytokines, including IL-1 β, IL-6, and IL-8, involved in inflammation, acute-phase response induction, and chemotaxis. IL-1 inhibition strategies with anakinra have shown efficacy as first and second lines of treatment. In this review, we will describe the main characteristics of biological drugs currently used for SAPHO syndrome. We also describe some of the promising therapeutic effects of ustekinumab, an antibody against the p40 subunit of IL-12 and IL-23, after failure of multiple drugs including anti-TNF-α and anakinra. We discuss the use and impact of the new anti-IL-1 antagonists involved in the IL-17 blockade, in particular for the most difficult-to-treat SAPHO cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum. 2012;42(3):254–65. doi:10.1016/j.semarthrit.2012.05.006.

    Article  PubMed  Google Scholar 

  2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8), e297. doi:10.1371/journal.pmed.0030297.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9(3):232–46. doi:10.1111/j.1610-0387.2010.07580.x.

    PubMed  Google Scholar 

  4. Stern SM, Ferguson PJ. Autoinflammatory bone diseases. Rheum Dis Clin North Am. 2013;39(4):735–49. doi:10.1016/j.rdc.2013.05.002.

    Article  PubMed  Google Scholar 

  5. Wipff J, Adamsbaum C, Kahan A, Job-Deslandre C. Chronic recurrent multifocal osteomyelitis. Joint Bone Spine. 2011;78(6):555–60. doi:10.1016/j.jbspin.2011.02.010.

    Article  PubMed  Google Scholar 

  6. Beretta-Piccoli BC, Sauvain MJ, Gal I, Schibler A, Saurenmann T, Kressebuch H, et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. Eur J Pediatr. 2000;159(8):594–601.

    Article  CAS  PubMed  Google Scholar 

  7. Rohekar G, Inman RD. Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis. Arthritis Rheum. 2006;55(4):665–9. doi:10.1002/art.22087.

    Article  CAS  PubMed  Google Scholar 

  8. Aljuhani F, Tournadre A, Tatar Z, Couderc M, Mathieu S, Malochet-Guinamand S, et al. The SAPHO syndrome: a single-center study of 41 adult patients. J Rheumatol. 2015;42(2):329–34. doi:10.3899/jrheum.140342. A recent case-series of patients with SAPHO syndrome providing clinical and therapeutic insights.

    Article  PubMed  Google Scholar 

  9. Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29(3):159–71.

    Article  CAS  PubMed  Google Scholar 

  10. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 2009;61(6):813–21. doi:10.1002/art.24540.

    Article  PubMed  Google Scholar 

  11. Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol. 1988;6(2):109–12.

    CAS  PubMed  Google Scholar 

  12. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic. 1987;54(3):187–96.

    CAS  PubMed  Google Scholar 

  13. Ombrello MJ. Advances in the genetically complex autoinflammatory diseases. Semin Immunopathol. 2015;37(4):403–6. doi:10.1007/s00281-015-0498-0. Updated view on the current classification of autoinflammatory diseases, their genetic basis and relevant undisclosed issues.

    Article  CAS  PubMed  Google Scholar 

  14. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147(3):155–74. doi:10.1016/j.clim.2013.03.016.

    Article  CAS  PubMed  Google Scholar 

  15. Ferguson PJ, Bing X, Vasef MA, Ochoa LA, Mahgoub A, Waldschmidt TJ, et al. A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone. 2006;38(1):41–7. doi:10.1016/j.bone.2005.07.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cassel SL, Janczy JR, Bing X, Wilson SP, Olivier AK, Otero JE, et al. Inflammasome-independent IL-1beta mediates autoinflammatory disease in Pstpip2-deficient mice. Proc Natl Acad Sci U S A. 2014;111(3):1072–7. doi:10.1073/pnas.1318685111. This paper shows the role of cytokine IL-1β in the Pstpip2-deficient mice affected by chronic multifocal osteomyelitis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hurtado-Nedelec M, Chollet-Martin S, Chapeton D, Hugot JP, Hayem G, Gerard B. Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes. J Rheumatol. 2010;37(2):401–9. doi:10.3899/jrheum.090456.

    Article  CAS  PubMed  Google Scholar 

  18. Colina M, Pippucci T, Moro MA, Marconi C, Magini P, Ciancio G, et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved? Clin Exp Rheumatol. 2012;30(3):451.

    CAS  PubMed  Google Scholar 

  19. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 2008;58(11):3461–70. doi:10.1002/art.23957.

    Article  CAS  PubMed  Google Scholar 

  20. Shepherd J, Little MC, Nicklin MJ. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol. 2004;122(3):665–9. doi:10.1111/j.0022-202X.2004.22305.x.

    Article  CAS  PubMed  Google Scholar 

  21. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360(23):2426–37. doi:10.1056/NEJMoa0807865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Firinu D, Barca MP, Lorrai MM, Perra S, Cabras S, Muggianu E, et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity. 2014;47(6):389–94. doi:10.3109/08916934.2014.906582.

    Article  CAS  PubMed  Google Scholar 

  23. Hofmann SR, Morbach H, Schwarz T, Rosen-Wolff A, Girschick HJ, Hedrich CM. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol. 2012;145(1):69–76. doi:10.1016/j.clim.2012.07.012.

    Article  CAS  PubMed  Google Scholar 

  24. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy R, Meyer O, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford). 2008;47(8):1160–7. doi:10.1093/rheumatology/ken185.

    Article  CAS  Google Scholar 

  25. Lasiglie D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A, et al. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One. 2011;6(5), e20014. doi:10.1371/journal.pone.0020014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ovadia A, Livneh A, Feld O, Ben-Zvi I, Kukuy E, Kivity S, et al. T helper 17 polarization in familial Mediterranean fever. Genes Immun. 2013;14(4):212–6. doi:10.1038/gene.2013.6.

    Article  CAS  PubMed  Google Scholar 

  27. Zuo RC, Schwartz DM, Lee CC, Anadkat MJ, Cowen EW, Naik HB. Palmoplantar pustules and osteoarticular pain in a 42-year-old woman. J Am Acad Dermatol. 2015;72(3):550–3. doi:10.1016/j.jaad.2014.07.014.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol. 2006;55(6):1066–71. doi:10.1016/j.jaad.2006.07.016.

    Article  PubMed  Google Scholar 

  29. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45(2):202–10. doi:10.1007/s12016-012-8351-x.

    Article  CAS  PubMed  Google Scholar 

  30. Borella E, Palma L, Zen M, Bettio S, Nalotto L, Gatto M, et al. The body against self: autoinflammation and autoimmunity. Isr Med Assoc J. 2014;16(10):608–10.

    PubMed  Google Scholar 

  31. Marzano AV, Cugno M, Trevisan V, Lazzari R, Fanoni D, Berti E, et al. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int J Immunopathol Pharmacol. 2011;24(2):451–60.

    CAS  PubMed  Google Scholar 

  32. Scarpa R, Lubrano E, Cozzi R, Ames PR, Oriente CB, Oriente P. Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? Br J Rheumatol. 1997;36(5):602–3.

    Article  CAS  PubMed  Google Scholar 

  33. Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162(1):100–7. doi:10.1111/j.1365-2249.2010.04201.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180(11):7423–30.

    Article  CAS  PubMed  Google Scholar 

  35. Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases. Medicine (Baltimore). 2015;94(45), e1818. doi:10.1097/MD.0000000000001818.

    Article  CAS  Google Scholar 

  36. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. 2004;279(4):2559–67. doi:10.1074/jbc.M308809200.

    Article  CAS  PubMed  Google Scholar 

  37. Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181(1):669–79.

    Article  CAS  PubMed  Google Scholar 

  38. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115(2):335–43. doi:10.1182/blood-2009-04-216085.

    Article  CAS  PubMed  Google Scholar 

  39. Kalke S, Perera SD, Patel ND, Gordon TE, Dasgupta B. The sternoclavicular syndrome: experience from a district general hospital and results of a national postal survey. Rheumatology (Oxford). 2001;40(2):170–7.

    Article  CAS  Google Scholar 

  40. Depasquale R, Kumar N, Lalam RK, Tins BJ, Tyrrell PN, Singh J, et al. SAPHO: what radiologists should know. Clin Radiol. 2012;67(3):195–206. doi:10.1016/j.crad.2011.08.014.

    Article  CAS  PubMed  Google Scholar 

  41. Fu Z, Liu M, Li Z, Fan Y, Zhang J, Zhang X, et al. Is the bullhead sign on bone scintigraphy really common in the patient with SAPHO syndrome? A single-center study of a 16-year experience. Nucl Med Commun. 2015. doi:10.1097/MNM.0000000000000451.

    Google Scholar 

  42. Jung J, Molinger M, Kohn D, Schreiber M, Pfreundschuh M, Assmann G. Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome. Semin Arthritis Rheum. 2012;42(3):266–70. doi:10.1016/j.semarthrit.2012.03.012.

    Article  CAS  PubMed  Google Scholar 

  43. Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther. 2009;11(5):R140. doi:10.1186/ar2812.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Murakami M, Masuda K, Utsunomiya R, Oda F, Namba C, Sayama K. Cefcapene pivoxil hydrochloride is a potentially new treatment for palmoplantar pustulosis with pustulotic arthro-osteitis. Dermatology. 2015;231(4):304–11. doi:10.1159/000439401.

    Article  CAS  PubMed  Google Scholar 

  45. Yabe H, Ohshima H, Takano Y, Koyanagi T, Usui H, Nojiri K, et al. Mucosal lesions may be a minor complication of SAPHO syndrome: a study of 11 Japanese patients with SAPHO syndrome. Rheumatol Int. 2010;30(10):1277–83. doi:10.1007/s00296-009-1138-6.

    Article  PubMed  Google Scholar 

  46. Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol. 2013;40(11):857–63. doi:10.1111/1346-8138.12272.

    Article  PubMed  Google Scholar 

  47. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford). 2004;43(5):658–61. doi:10.1093/rheumatology/keh149.

    Article  CAS  Google Scholar 

  48. Solau-Gervais E, Soubrier M, Gerot I, Grange L, Puechal X, Sordet C, et al. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford). 2006;45(3):339–42. doi:10.1093/rheumatology/kei160.

    Article  CAS  Google Scholar 

  49. Colina M, La Corte R, Trotta F. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol. 2009;27(1):112–5.

    CAS  PubMed  Google Scholar 

  50. Delattre E, Guillot X, Godfrin-Valnet M, Prati C, Wendling D. SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients. Joint Bone Spine. 2014. doi:10.1016/j.jbspin.2014.01.017.

    Google Scholar 

  51. Hayama K, Inadomi T, Fujisawa D, Terui T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol. 2010;20(6):758–62. doi:10.1684/ejd.2010.1109.

    CAS  PubMed  Google Scholar 

  52. Kundu BK, Naik AK, Bhargava S, Srivastava D. Diagnosing the SAPHO syndrome: a report of three cases and review of literature. Clin Rheumatol. 2013;32(8):1237–43. doi:10.1007/s10067-013-2251-1.

    Article  PubMed  Google Scholar 

  53. Gorecki P, Stockmann P, Distler JHW, Wuest W, Schmidt D, Neukam FW, et al. Implication of bisphosphonate use in the treatment of SAPHO syndrome: case report and discussion of current literature. J Med Hypotheses Ideas. 2015;9(2):72–8. doi:10.1016/j.jmhi.2015.04.002.

    Article  Google Scholar 

  54. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis. 2002;61(4):375–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002;46(7):1965–8. doi:10.1002/art.10539.

    Article  PubMed  Google Scholar 

  56. Burgemeister LT, Baeten DL, Tas SW. Biologics for rare inflammatory diseases: TNF blockade in the SAPHO syndrome. Neth J Med. 2012;70(10):444–9.

    CAS  PubMed  Google Scholar 

  57. Hayem G, M’Barek RB, Toussirot E, Compaore C, Pham T, Houvenagel E et al. Abstracts of the American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting. November 6–11, 2010. Atlanta, Georgia, USA. Arthritis Rheum. 2010;62 Suppl 10:1. doi:10.1002/art.30032.

  58. Laveti D, Kumar M, Hemalatha R, Sistla R, Naidu VG, Talla V, et al. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets. 2013;12(5):349–61.

    Article  CAS  PubMed  Google Scholar 

  59. Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo Jr BF, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88. doi:10.1016/j.jaad.2011.01.032.

    Article  CAS  PubMed  Google Scholar 

  60. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89(6):595–600. doi:10.2340/00015555-0747.

    Article  CAS  PubMed  Google Scholar 

  61. Adisen E, Gurer MA. Therapeutic options for palmoplantar pustulosis. Clin Exp Dermatol. 2010;35(3):219–22. doi:10.1111/j.1365-2230.2009.03520.x.

    Article  CAS  PubMed  Google Scholar 

  62. Delage M, Samimi M, Atlan M, Machet L, Lorette G, Maruani A. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol. 2011;91(2):169–71. doi:10.2340/00015555-1025.

    Article  PubMed  Google Scholar 

  63. Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, Novoa-Medina J, Valeron Almazan P, Santana Medina N, et al. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm Venereol. 2010;90(5):531–2. doi:10.2340/00015555-0895.

    Article  PubMed  Google Scholar 

  64. Moll C, Hernandez MV, Canete JD, Gomez-Puerta JA, Soriano A, Collado A, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum. 2008;37(5):299–306. doi:10.1016/j.semarthrit.2007.08.004.

    Article  CAS  PubMed  Google Scholar 

  65. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford). 2006;45(6):730–3. doi:10.1093/rheumatology/kei221.

    Article  CAS  Google Scholar 

  66. De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185–7.

    PubMed  Google Scholar 

  67. Salles M, Olive A, Perez-Andres R, Holgado S, Mateo L, Riera E, et al. The SAPHO syndrome: a clinical and imaging study. Clin Rheumatol. 2011;30(2):245–9. doi:10.1007/s10067-010-1560-x.

    Article  PubMed  Google Scholar 

  68. Fruehauf J, Cierny-Modre B, Caelen Lel S, Schwarz T, Weinke R, Aberer E. Response to infliximab in SAPHO syndrome. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.10.2008.1145.

  69. Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol. 2010;37(8):1699–704. doi:10.3899/jrheum.091086.

    Article  CAS  PubMed  Google Scholar 

  70. Firinu D, Murgia G, Lorrai MM, Barca MP, Peralta MM, Manconi PE, et al. Biological treatments for SAPHO syndrome: an update. Inflamm Allergy Drug Targets. 2014;13(3):199–205.

    Article  CAS  PubMed  Google Scholar 

  71. Zhang LL, Zhao JX, Liu XY. Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study. Rheumatol Int. 2012;32(7):1963–5. doi:10.1007/s00296-011-1916-9.

    Article  CAS  PubMed  Google Scholar 

  72. Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, Fernandez-Pugnaire MA, Ortego-Centeno N. Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol. 2010;90(3):301–2. doi:10.2340/00015555-0822.

    Article  PubMed  Google Scholar 

  73. Garcovich S, Amelia R, Magarelli N, Valenza V, Amerio P. Long-term treatment of severe SAPHO syndrome with adalimumab: case report and a review of the literature. Am J Clin Dermatol. 2012;13(1):55–9. doi:10.2165/11593250-000000000-00000.

    Article  PubMed  Google Scholar 

  74. Henriques CC, Sousa M, Panarra A, Riso N. The dark side of SAPHO syndrome. BMJ Case Rep. 2011. doi:10.1136/bcr.11.2011.5197.

    PubMed  PubMed Central  Google Scholar 

  75. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90(2):183–5. doi:10.2340/00015555-0777.

    Article  PubMed  Google Scholar 

  76. Kamata Y, Minota S. Successful treatment of a patient with SAPHO syndrome with certolizumab pegol. Rheumatol Int. 2015;35(9):1607–8. doi:10.1007/s00296-015-3263-8.

    Article  PubMed  Google Scholar 

  77. Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A, et al. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology. 2013;227(4):305–10. doi:10.1159/000354263.

    Article  CAS  PubMed  Google Scholar 

  78. Firinu D, Lorrai MM, Barca MP, Peralta MM, Mura MN, Perra S, et al. Increased peripheral T(H)17 Cells in SAPHO syndrome: a novel target for treatment? Allergy. 2013;68:198–9.

    Google Scholar 

  79. Colina M, Pizzirani C, Khodeir M, Falzoni S, Bruschi M, Trotta F, et al. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford). 2010;49(7):1416–8. doi:10.1093/rheumatology/keq074.

    Article  CAS  Google Scholar 

  80. Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis. 2012;71(6):1098–100. doi:10.1136/annrheumdis-2011-200743. The largest published series of SAPHO patients treated with Anakinra.

    Article  CAS  PubMed  Google Scholar 

  81. Fujita S, Kosaka N, Mito T, Hayashi H, Morita Y. Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis. Int J Rheum Dis. 2015;18(4):476–9. doi:10.1111/1756-185X.12525.

    Article  CAS  PubMed  Google Scholar 

  82. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163(5):1116–8. doi:10.1111/j.1365-2133.2010.09897.x.

    Article  CAS  PubMed  Google Scholar 

  83. Edlund E, Johnsson U, Lidgren L, Pettersson H, Sturfelt G, Svensson B, et al. Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis. 1988;47(10):809–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Jappe U, Boit R, Farrar MD, Ingham E, Sandoe J, Holland KT. Evidence for diversity within Propionibacterium acnes: a comparison of the T-cell stimulatory activity of isolates from inflammatory acne, endocarditis and the laboratory. J Eur Acad Dermatol Venereol. 2004;18(4):450–4. doi:10.1111/j.1468-3083.2004.00950.x.

    Article  CAS  PubMed  Google Scholar 

  85. Hayem G, Hurtado-Nedelec M, Chollet-Martin S. The immune response in SAPHO syndrome: deficiency, hyper- responsiveness, or both? Curr Rheumatol Rev. 2013;9(1):11–4.

    Article  PubMed  Google Scholar 

  86. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol. 2011;24(1):269–74.

    CAS  PubMed  Google Scholar 

  87. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–55. doi:10.1136/annrheumdis-2012-202220.

    Article  CAS  PubMed  Google Scholar 

  88. Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92(4):362–4. doi:10.2340/00015555-1376.

    Article  CAS  PubMed  Google Scholar 

  89. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–52. doi:10.1038/nrd3800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Sanna M, Firinu D, Manconi PE, Pisanu M, Murgia G, Piras V, et al. The salivary proteome profile in patients affected by SAPHO syndrome characterized by a top-down RP-HPLC-ESI-MS platform. Mol Biosyst. 2015. doi:10.1039/c4mb00719k.

    Google Scholar 

  91. Colina M, Trotta F. Clinical and radiological characteristics of SAPHO syndrome. Curr Rheumatol Rev. 2013;9(1):22–7. A paper describing the key aspects of the disease.

    Article  PubMed  Google Scholar 

  92. Marotte H, Cimaz R. Etanercept—TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014. doi:10.1517/14712598.2014.896334.

    PubMed  Google Scholar 

  93. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford). 2010;49(8):1505–12. doi:10.1093/rheumatology/keq122.

    Article  CAS  Google Scholar 

  94. Lukens JR, Gross JM, Calabrese C, Iwakura Y, Lamkanfi M, Vogel P, et al. Critical role for inflammasome-independent IL-1beta production in osteomyelitis. Proc Natl Acad Sci U S A. 2014;111(3):1066–71. doi:10.1073/pnas.1318688111. This paper shows the role of IL-1β dysregulation and identifies PSTPIP2 as a negative regulator of caspase-1–autonomous IL-1β production in chronic multifocal osteomyelitis of mice.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Pham TN, Rahman P, Richardson VJ. Divergent effects of infliximab and anakinra therapies on macrophage phenotype from patients with refractory rheumatoid arthritis. Int J Immunopathol Pharmacol. 2010;23(2):491–501.

    CAS  PubMed  Google Scholar 

  96. Castrichini M, Lazzerini PE, Gamberucci A, Capecchi PL, Franceschini R, Natale M, et al. The purinergic P2x7 receptor is expressed on monocytes in Behcet’s disease and is modulated by TNF-alpha. Eur J Immunol. 2013. doi:10.1002/eji.201343353.

    PubMed  Google Scholar 

  97. Scholtysek C, Kronke G, Schett G. Inflammation-associated changes in bone homeostasis. Inflamm Allergy Drug Targets. 2012;11(3):188–95.

    Article  CAS  PubMed  Google Scholar 

  98. Abu-Amer Y, Darwech I, Otero J. Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. Autoimmunity. 2008;41(3):204–11. doi:10.1080/08916930701694543.

    Article  CAS  PubMed  Google Scholar 

  99. Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92(3):320–1. doi:10.2340/00015555-1229.

    Article  CAS  PubMed  Google Scholar 

  100. Hermanns-Le T, Berardesca E, Pierard GE, Lesuisse M, Pierard-Franchimont C. Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. J Biomed Biotechnol. 2012;2012:413767. doi:10.1155/2012/413767.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Allergy and Clinical Immunology, Department of Medical Sciences “M. Aresu”, University of Cagliari, Asse Didattico “E1” – Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy

    Davide Firinu, Paolo Emilio Manconi & Stefano R. Del Giacco

  2. Respiratory Epidemiology, Occupational Medicine and Public Health Group, National Heart and Lung Institute, Imperial College London, Manresa Road, SW3 6LR, London, UK

    Vanessa Garcia-Larsen

Authors
  1. Davide Firinu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vanessa Garcia-Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Emilio Manconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano R. Del Giacco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano R. Del Giacco.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with the Helsinki declaration and its amendments and institutional research committee standards.

Additional information

Topical Collection on Orphan Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Firinu, D., Garcia-Larsen, V., Manconi, P.E. et al. SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment. Curr Rheumatol Rep 18, 35 (2016). https://doi.org/10.1007/s11926-016-0583-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0583-y

Keywords

Search

Navigation